Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
Authors:
- Alessandro MusengaAMAlessandro Musenga
- Maria Augusta RaggiMRMaria Augusta Raggi
- 20 December 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 17 (1) , 61-75
Abstract
Iloperidone is a new-generation atypical antipsychotic agent, acting as a serotonin/dopamine (5-HT2A/D2) antagonist, under development by Vanda Pharmaceuticals for the treatment of schizophrenia, bipolar disorder and other psychiatric conditions. Chemically, iloperidone is a benzisoxazole, like risperidone, and shows a multiple receptor binding profile, sharing this feature with the other atypical antipsychotic agents. Administered orally, the drug is highly bound to plasma proteins and extensively metabolised. Several clinical trials have been carried out, to check efficacy, safety and side effects. In order to introduce iloperidone as an agent for the treatment of schizophrenia, a short overview of the disease and of the most important antipsychotic drugs available or under development will be reported. Iloperidone pharmacokinetics and pharmacodynamics are presented herein, together with an evaluation of clinical safety and efficacy results.Keywords
This publication has 50 references indexed in Scilit:
- Risk factors for schizophrenia — All roads lead to dopamineEuropean Neuropsychopharmacology, 2007
- Cost-Effectiveness Analysis of Schizophrenia Relapse PreventionClinical Drug Investigation, 2006
- Pharmacotherapy of Schizophrenia: The Past, Present and FutureCurrent Drug Therapy, 2006
- Variations in the Incidence of Schizophrenia: Data Versus DogmaSchizophrenia Bulletin, 2005
- Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.Current Medicinal Chemistry, 2004
- SchizophreniaNew England Journal of Medicine, 2003
- Therapeutic Drug Monitoring: Chemical-Clinical Correlations of Atypical Antipsychotic DrugsCurrent Medicinal Chemistry, 2002
- Binding of antipsychotic drugs to human brain receptorsLife Sciences, 2000
- Pharmacologic strategies for augmenting cognitive performance in schizophreniaBiological Psychiatry, 1999
- A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory SchizophreniaNew England Journal of Medicine, 1997